207 related articles for article (PubMed ID: 6374968)
61. Maleness as risk factor for slowly progressive IDDM.
Kobayashi T; Nakanishi K; Sugimoto T; Itoh T; Murase T; Kosaka K; Tsuji K
Diabetes Care; 1989 Jan; 12(1):7-11. PubMed ID: 2653752
[TBL] [Abstract][Full Text] [Related]
62. Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion.
Lev-Ran A; Hwang D; Barseghian G; Hill LR
Diabete Metab; 1986 Dec; 12(6):325-8. PubMed ID: 3545932
[TBL] [Abstract][Full Text] [Related]
63. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.
Maruyama T; Tanaka S; Shimada A; Funae O; Kasuga A; Kanatsuka A; Takei I; Yamada S; Harii N; Shimura H; Kobayashi T
J Clin Endocrinol Metab; 2008 Jun; 93(6):2115-21. PubMed ID: 18397986
[TBL] [Abstract][Full Text] [Related]
64. Insulin secretory capacity in Singapore diabetic subjects.
Thai AC; Yeo PP; Chan L; Wang KW; Lui KF; Cheah JS; Tan BY
Ann Acad Med Singap; 1985 Apr; 14(2):191-3. PubMed ID: 3898977
[TBL] [Abstract][Full Text] [Related]
65. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis.
Niskanen L; Karjalainen J; Siitonen O; Uusitupa M
J Intern Med; 1994 Sep; 236(3):263-70. PubMed ID: 8077881
[TBL] [Abstract][Full Text] [Related]
66. [Indicators for insulin therapy in late elderly patients with type 2 diabetes mellitus--the relationship between plasma C-peptide on glucagon load test and insulin therapy].
Miyamoto M
Nihon Ronen Igakkai Zasshi; 2009 May; 46(3):244-9. PubMed ID: 19521045
[TBL] [Abstract][Full Text] [Related]
67. Clinical heterogeneity of insulin dependent diabetes mellitus in Korea.
Lee KU; Kim SW; Park JY; Ko KS; Rhee BD; Min HK
Diabetes Res Clin Pract; 1995 Feb; 27(2):159-62. PubMed ID: 7607055
[TBL] [Abstract][Full Text] [Related]
68. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide.
Aoki Y
Diabetes Res Clin Pract; 1991 Dec; 14(3):165-73. PubMed ID: 1778109
[TBL] [Abstract][Full Text] [Related]
69. Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy.
Nakanishi K; Kobayashi T; Inoko H; Tsuji K; Murase T; Kosaka K
Diabetes; 1995 Nov; 44(11):1334-9. PubMed ID: 7589833
[TBL] [Abstract][Full Text] [Related]
70. Insulin secretory responses in patients with glucose intolerance due to extra-pancreatic causes. Comparison with idiopathic diabetes mellitus.
Kosaka K; Kuzuya T; Hagura R; Akanuma Y; Kanazawa Y
Endocrinol Jpn; 1981 Aug; 28(4):487-98. PubMed ID: 6763894
[TBL] [Abstract][Full Text] [Related]
71. Effect of alcohol on glucose tolerance in normal and noninsulin-dependent diabetic subjects.
Singh SP; Kumar Y; Snyder AK; Ellyin FE; Gilden JL
Alcohol Clin Exp Res; 1988 Dec; 12(6):727-30. PubMed ID: 3064631
[TBL] [Abstract][Full Text] [Related]
72. Heterogeneity of serum basal C peptide levels amongst Arab patients with diabetes mellitus.
Abdella N; Luqman W; Hassan M; Salman A
Diabetes Res; 1988 Sep; 9(1):47-50. PubMed ID: 3149222
[TBL] [Abstract][Full Text] [Related]
73. Professional continuous glucose monitoring for the identification of type 1 diabetes mellitus among subjects with insulin therapy.
Chen YC; Huang YY; Li HY; Liu SW; Hsieh SH; Lin CH
Medicine (Baltimore); 2015 Jan; 94(3):e421. PubMed ID: 25621692
[TBL] [Abstract][Full Text] [Related]
74. C-peptide response to oral glucose and its clinical role in elderly people.
Wickramasinghe LS; Chazan BI; Farrow M; Bansal SK; Basu SK
Age Ageing; 1992 Mar; 21(2):103-8. PubMed ID: 1575087
[TBL] [Abstract][Full Text] [Related]
75. Clinical correlates of basal hepatic glucose output and metabolic clearance rate of glucose using glucose-C-peptide-body mass indexes in ambulatory type 2 diabetic patients.
Osei K; Holland GC
Diabetes Res; 1987 Aug; 5(4):181-7. PubMed ID: 3665344
[TBL] [Abstract][Full Text] [Related]
76. [Glucose homeostasis in mucoviscidosis].
Skopnik H; Schüttler A; Döhmen H; Geron M; Heimann G
Klin Padiatr; 1989; 201(2):112-7. PubMed ID: 2654455
[TBL] [Abstract][Full Text] [Related]
77. Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: its relation to clinical and metabolic features.
Bonora E; Coscelli C; Butturini U
Acta Diabetol Lat; 1984; 21(4):375-83. PubMed ID: 6397028
[TBL] [Abstract][Full Text] [Related]
78. C-peptide in diabetes mellitus treated with insulin. A 3-year epidemiological study on the island of Falster, Denmark.
Nielsen NV; Tronier B
Diabetes Res; 1986 Nov; 3(9):475-8. PubMed ID: 3549123
[TBL] [Abstract][Full Text] [Related]
79. Islet cell surface antibodies in diabetes and their possible influence on glucose tolerance.
Ohgawara H; Hirata Y
Tohoku J Exp Med; 1984 Feb; 142(2):211-6. PubMed ID: 6372161
[TBL] [Abstract][Full Text] [Related]
80. The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study.
Dario T; Riccardo G; Silvia P; Mikiko W; Daria M; Andrea P; Giuseppe D; Elvira F; Paolo P; Silvia M
Acta Diabetol; 2021 Apr; 58(4):411-417. PubMed ID: 33185778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
